Advances in targeted therapy for acute myeloid leukemia

Biomarker Research

Peter Y. Z. Jiang¹  Yongping Song²  Jifeng Yu³  Hao Sun³  Xia Zhang³  Zhongxing Jiang³  Yingmei Li³ 

[1] Department of Hematology and Oncology, The Everett Clinic and Providence Regional Cancer Partnership;The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital;The First Affiliated Hospital of Zhengzhou University;

关键词: Targeted therapy;    Gene mutation;    Acute myeloid leukemia (AML);   

DOI  :  10.1186/s40364-020-00196-2

来源: DOAJ

【 摘 要 】

Abstract Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than half of a century. Although much progress has been made toward improving treatment related mortality rate in the past few decades, long term overall survival has stagnated. Exciting developments of gene mutation-targeted therapeutic agents are now changing the landscape in AML treatment. New agents offer more clinical options for patients and also confer a more promising outcome. Since Midostaurin, a FLT3 inhibitor, was first approved by US FDA in 2017 as the first gene mutation-targeted therapeutic agent, an array of new gene mutation-targeted agents are now available for AML treatment. In this review, we will summarize the recent advances in gene mutation-targeted therapies for patients with AML.

【 授权许可】

Unknown